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Table 
TIMI before PCI TIMI O+l TIMI 2+3 
n= 27 171 
TIMI 3 after PCI (%) 96.2 92.5 
MPG 3 after PCI (%) 19.1 49.0 
Death (%) 7.4 2.3 
Re-AMI (%) 7.4 0 
PC 
NS 
0.01 
NS 
NS 
Re-PCI (%I 
MACE (%) 
849F0 
3.7 0.6 NS 
18.5 2.9 0.001 
ORAL CONTRIBUTIONS 
Featured Oral Session...Using Risk 
Stratification Tools for Treatment 
Decisions in Patients With Acute 
Coronary Syndromes 
Tuesday, April 01, 2003, 2:00 p.m.-3:30 p.m. 
McCormick Place, Vista S406 A 
2:15 p.m. 
849FO-2 Degree of Baseline Risk Should, But Does Not, 
Influence Treatment Decisions in Non-ST Elevation 
Acute Coronary Syndromes: Evidence From 
international Clinical Trials 
Padma Kaul, L. Kristin Newby. Yuling Fu. Harrington Robert, Christopher Granger, Frans 
J. Van de Wed. Daniel Mark, Paul W. Armstrong, University of Alberta, Edmonton, AB, 
Canada, Duke Clinical Research Institution, Durham, NC 
Background: Increasing ST-segment depression (ST-dep) on the baseline ECG is an 
important tool for risk-stratification in non-ST elevation (NSTE) acute coronary syn- 
dromes (ACS). In particular, the presence of ST-dep identifies patients with the greatest 
ischemic burden most likely to benefit from early invasive therapy. The ACCiAHA Guide- 
fines denote new or presumably new ST-dep a class IA recommendation for early inva- 
sive strategy. However, whether this recommendation is followed in practice is not 
known. 
Methods: We examined temporal and international patterns in the extent to which the 
degree of ST-dep influences the use of angiography, PCI and CABG over a five-year 
time frame (‘94 - ‘99). 
Results: Patients enrolled in GUSTO-Pb (5632) PARAGON-A (1246) and PARAGON-B 
(855) were included. 
Conclusions: Irrespective of region of enrollment, there appears to be ltttle relationship 
between the extent of ST-dep and the use of invasive procedures. These data under- 
score the need for better implementation of guidelines to captitalize on unrealized oppor- 
tunities for more efficient use of angiography and revascularization procedures among 
high risk NSTE ACS patients. 
category 
N 
us 
Angiography 
PC 
CABG 
Canada 
Angiography 
PCI 
CABG 
Europe 
Angiography 
PCI 
CABG 
No ST-dep 
3694 
61 
33 
17 
46 
19 
6 
53 
20 
9 
lmm ST-dep ST-dep>=Zmm 
2619 1420 
60 77 
28 29 
24 33 
49 
15 
15 
51 
19 
11 
40 
12 
14 
50 
16 
16 
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2:30 p.m. 
849FO-3 Abciximab Treatment Does Not influence Levels of 
Inflammatory Markers in Patients With Acute Coronary 
Syndrome 
Stefan James, Paul W. Armstrong, Robert M. Califf, Agneta Siegbahn. Maarten 
Simoons, University Hospital, Uppsala, Sweden 
Background: The GUSTO IV trial included 7800 patients with ACS without 
ST-elevation and the patients were not scheduled for early revascularization. 
There was no clinical benefit of abciximab infusion for 24 or 46 hours compared 
to placebo. Through cross-reactivity with other tntegrin receptors, abcedmab 
may influence the inflammation system, which has emerged as one plausible 
explanation for unexpected lack of clinical benefit. 
Methods: In the dalteparin substudy all patients received dalteparin in stead of unfrac- 
tionated heparin. Serial serum samples for analyses of Interleukin-6 (k-6) and high sensi- 
tive C-reactive protein (CRP) were obtained from all patients (11~404) at selected sites. 
Results: 
II-6 @g/L) Placebo 
Abciximab 24 h 
Abciximab 46 h 
P’ 
Baseline 24h 46h 72h 
5.7 7.6 6.1 6.6 
5.2 7.0 6.7 6.1 
5.3 7.9 8.1 6.6 
“.s “.S n.s n.s 
CRP(mg/L) Placebo 4.4 a.4 6.4 7.7 
Abciximab 24 h 4.2 7.0 6.7 6.1 
Abciximab 46 h 4.9 9.2 8.2 9.0 
P n.s n.s n.s n.s 
‘Kruskal-Wallis test 
Conclusion: In patients wtth non-ST elevation ACS levels of inflammatory markers 
raised early. However, the inflammatory activity, as measured by levels of II-6 and CRP, 
was not influenced by abciximab treatment. 
2:45 p.m. 
849FO-4 Suboptimal Adherence to the ACC/AHA Non-ST 
Elevation Acute Coronary Syndrome Practice 
Guidelines for Patients With Positive Troponin Levels 
Matthew T. Roe, Eric D. Peterson, Yun Li, Robert A. Harrington, Charles V. Pollack. 
Ralph G. Brindis, Robert H. Christenson, Sidney C. Smith, Jr., W. Brtan Gibler, E. 
Magnus Ohman, Duke Clinical Research Institute, Durham, NC 
Background: ACC/AHA guidelines for the treatment of non-ST-elevation acute coronary 
syndromes (NSTE ACS) recommend aggressive early management for patrents with 
positive troponin levels, but the influence of troponin results on the quality of care pro- 
vided to ACS patients has not been evaluated. 
Methods: Troponin results were recorded in 16,079 of 16,905 high-risk patients with 
NSTE ACS (ischemic ST-segment changes or positive cardiac markers) in the CRU- 
SADE quality improvement initiative. Troponin results were determined to be positive 
(any value within the first 24 hours > upper limit of normal) in 12,365 of 16,079 (75%) 
patients. Use of acute therapies and interventions given Type IA recommendattons by 
the ACC/AHA guidelines was evaluated in patients without contraindications to the given 
therapies stratified by troponin results. 
Results: The table shows adjusted odds ratios for the Ikkelihood that troponin-positive 
patients received the grven treatment. Conclusions: NSTE ACS patients with positive 
troporiins are managed more aggressively than patients with negative troponins, but type 
IA recommendations from the ACC/AHA guidelines are under-ublized in all patients. 
Increased use of evidence-based therapies for patients with positive troponins may 
reduce the high mortality seen in this group. 
Positive Negative Adjusted 95% Adjusted 
Troponins Troponins Odds Ratio Cl P-Values 
Aspwin < 24 hrs(%) 90.7 88.6 1.42 1.24. <O.OOOl 
1.64 
Clopidogrel c 24 hrs 36.3 32.9 1.36 1.24. <O.OOOl 
(%) 1.49 
Heparin < 24 hrs 85.5 76.9 2.16 1.94 <0.0001 
(%) 2.40 
GP Ilb/llla Inhibitors 33.6 22.7 2.16 1.95. <0.0001 
< 24 hrs (%) 2.40 
Early Cardiac Cath 44.2 40.3 1.54 1.40 ~0.0001 
< 46 hrs (%) 1.70 
In-Hospital Mortality 5.9 2.6 1.76 1.36. c0.0001 
(%) 2.26 
